Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
about
The Role of Toll-Like Receptors in Hematopoietic MalignanciesEstablished and emerging targeted therapies in the myelodysplastic syndromes.Improving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models.How we manage immune thrombocytopenia in the elderly.Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes.Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case reportTP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.The risk of infections in patients with myelodysplastic syndromes in 2016.Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome.Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?Loss of toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS.Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes.Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling.Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML
P2860
Q28077740-9D4F52B9-E2E3-4AA7-BA5A-B8005B0E5353Q30245476-0C4C3C1E-DC75-4D49-81FB-314C217BDA09Q31054529-CEC216C8-BEA7-4A46-AB53-40F5000D9517Q33431371-B754F20B-0ECB-4FB6-88A6-7E1DE502D531Q33442617-6F7FEDEA-D183-4294-9296-E1B3D19E0DC5Q37204110-D5E3D77B-23F9-45AE-8A90-71DA476F39E9Q37392696-90EE252A-8655-4000-B968-F3B5213D55BCQ38372745-3C23F986-5F95-4071-AA11-E51581BD1F0CQ38648597-A5D598EB-CE2D-437A-BB09-56BA25C7AE88Q38678113-4D529F27-BD48-4D38-97D9-921DDEAA20ECQ38813702-3DEDE08D-A17D-4C32-BF65-7E78B4B036EAQ39069357-EDF57A7A-133C-4C15-9356-9C67483E110EQ39413114-BC39F0BD-223B-464E-ABD4-721A748FE71CQ39601934-1E67B56C-E03D-4A1A-9D3A-06A709FD5A8FQ40261354-0CF10C24-D321-497E-9E77-A109150B5D25Q40427129-126E10F2-D972-4B83-BF47-AC5BFC8C0B9FQ42025658-A47FE27F-922D-4654-A8BF-3B6F2A13290BQ42693220-E439BD52-1904-47E1-A61A-FC1B5660C8B0Q46105174-6FDEB591-F9F6-40CD-B239-BDDBA1BA612AQ47099325-C56BCB2C-8D08-4654-84FA-25993714B9AEQ48123200-596C7D63-4428-4684-8AAD-4650DBDB60BEQ48198254-585CB2A4-62A8-4BD2-A675-48C3285A9EEDQ48214681-D7A11A7E-CD25-4E11-80A1-40C7ACCF68D5Q48633334-A919EE9E-1CF5-4151-9B85-A8E9CC5A11A3Q49875948-B0F4A295-539E-4DB3-8740-211092A87655Q50239003-199DC078-AF01-4009-B5C0-1BDB22274C2EQ53820609-93932117-1820-4B1D-BD8C-BD05F43935E4Q54602748-2572660E-BBF6-4A6E-B273-1563CEF329E4Q55248017-64273F81-DCFF-4F6B-A7D7-717B57222A52Q58733645-DCB61C76-3338-4472-9F26-F3105486CFFE
P2860
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@ast
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@en
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@nl
type
label
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@ast
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@en
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@nl
prefLabel
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@ast
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@en
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@nl
P2860
P3181
P356
P1476
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
@en
P2093
Guillermo Garcia-Manero
P2860
P304
P3181
P356
10.1002/AJH.24102
P407
P577
2015-09-01T00:00:00Z